When Promising Treatments Are Left on the Shelf, Families Cannot Stay Silent

Of 659 rare disease trials examined, 30.2% were discontinued before completion. Patient organizations can help address this problem by connecting families with registries, researchers, and appropriate clinical trials.

For parents in the rare disease community, the word “pipeline” does not sound like a business term. It sounds like hope. Somewhere in that pipeline may be the treatment that helps our child sit, speak, breathe, eat independently, or simply live longer. That is why recent changes in rare disease research should concern every family, not only scientists and pharmaceutical executives.

Citeline’s 2026 review counted 22,940 active drug candidates across the global pharmaceutical pipeline. Rare disease programs declined from 7,721 in 2025 to 7,618 in 2026, a net loss of 103 programs. Citeline cautioned that changes in its counting methods may explain part of the overall decline, but the numbers still show how quickly research priorities can shift. Rare disease programs remain roughly one-third of the global pipeline, yet being listed in a pipeline does not guarantee that a treatment will reach patients.

Even after a clinical trial begins, the path remains fragile. A study examining 659 registered rare disease trials found that 30.2 percent were discontinued. The most common reported reason was insufficient patient enrollment, accounting for 32.1 percent of discontinued trials. For common diseases, researchers may recruit from thousands of nearby patients. Rare disease trials must often locate a small number of eligible families scattered across countries, languages, healthcare systems, and financial circumstances.

Then there are treatments that never officially “fail.” They simply disappear.

Discontinued Rare Disease Research

The Children’s Tumor Foundation has helped draw attention to an estimated 5,000 or more shelved drug candidates. Many were discontinued for reasons unrelated to safety or effectiveness. A company may acquire a smaller biotech for one promising product and set aside the rest. A partnership may collapse. Funding may run out. Leadership may redirect investment toward larger and more profitable markets. What looks like a strategic adjustment in a boardroom can feel like a door closing for a family with no other options.

There is also proof that shelved does not have to mean finished. The Children’s Tumor Foundation helped connect a discontinued Pfizer compound with SpringWorks Therapeutics. That drug, now known as Gomekli, was eventually approved for certain patients with neurofibromatosis type 1. It is a powerful example of what can happen when patient organizations, researchers, and industry partners refuse to let promising science disappear.

Policy matters too. The Rare Pediatric Disease Priority Review Voucher program was recently extended, but under current law it is scheduled to end after September 30, 2029. This program gives companies an important incentive to develop treatments for rare pediatric conditions. Its temporary extension is encouraging, but it also reminds us that rare disease progress depends on continued advocacy, stable research funding, and lawmakers who understand what is at stake.

This is why organizations such as Teach RARE need support. Nonprofits build the community infrastructure that research depends on. We educate families, connect communities, raise awareness, encourage participation in registries and natural history studies, and help parents understand opportunities that may otherwise pass unnoticed. We also help families tell their stories in ways that researchers, companies, donors, and policymakers cannot ignore.

Parents can take action by joining a patient registry, keeping medical records organized, asking researchers about natural history studies, sharing verified trial information, contacting elected officials, volunteering, fundraising, or donating to trusted rare disease organizations. Not every family can give money, but every family has knowledge, experience, and a voice.

A treatment sitting on a shelf cannot help a child. A promising trial without enough participants cannot continue. A nonprofit without support cannot build the bridges needed to move research forward.